undamentalytics Newsletter
Sign in

Akso Health Group (AHG) stock

Add to watchlist

Add holding +

NASDAQ: AHG Nasdaq Health Care Services

E Fundamentals grade

Akso Health Group is a US-listed company in the health care services industry. Its financial year ends in March.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: our cash-flow value ($0.00) is 0.00x the share price ($1.31); a gap this wide almost always means a data problem.

Price vs value

Under review: our cash-flow value ($0.00) is 0.00x the share price ($1.31); a gap this wide almost always means a data problem. We'll show the comparison once resolved.

Akso Health Group valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds9 adding, 1 cuttingOf 2 active managers that changed their stake, 1 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Akso Health Group files

Where Akso Health stands after its latest Filing

Revenue for the twelve months was $14m, down 6.4% on a year earlier, against growth of 512.1% a quarter earlier. Free-cash-flow margin fell to -92.5% from -2.1% a year earlier. Operating margin narrowed to -149.7% from -54.3%. The diluted share count is up 153.5% on a year earlier, which dilutes existing holders. It passes 2 of our 2 financial-health checks.

Our model value for Akso Health Group is under review, so past values are not shown until it is resolved.

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Akso Health Group's trailing-twelve-month revenue fell 6.4% year on year, with a free-cash-flow margin of -92.5%. Where it lags: change in growth rate of -518.5pp ranks 41 of 41 health care services companies we cover.

Our discounted-cash-flow model values the business at — per share in the base case (—–$0.0 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Share count rising (dilution): Diluted shares outstanding rose 153.5% year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Margins widening. Operating margin is up 975.7 points on a year ago.

Things to watch

  • Revenue shrinking. Revenue fell 6.4% over the last 12 months.
  • Growth slowing. The growth rate is 518.5 points lower than a quarter earlier.
  • Loss-making. Operating margin is -149.7%: costs exceed revenue.
  • Burning cash. Free cash flow was -92.5% of revenue over the last 12 months.
  • Share dilution. Diluted shares rose 153.5% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 96% and a beta of -0.1 against the S&P 500.

Latest results

Earnings per share
-$0.45 against an average estimate of $0.00: beat by 0.0%

Akso Health Group's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+4.2%
  • 1 week+3.4%
  • 1 month+14.2%
  • This year-19.9%
  • 1 year-19.0%
  • 5 years-70.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$13.8M
Operating margin
-149.7%
Net margin
-135.0%
EPS (TTM, diluted)
$-0.03

Growth

Revenue growth
−6.4%
Change in growth rate
−518.5 pts
Share count change
+153.5%

Cash

Free cash flow (TTM)
-$12.8M
FCF margin
-92.5%

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

No recent updates are available for AHG from the sources we follow. See filings →

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Akso Health Group valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: held for review: our cash-flow value ($0.00) is 0.00x the share price ($1.31); a gap this wide almost always means a data problem.

Our value per share comes from a discounted-cash-flow model of Akso Health Group's free cash flow after stock-based pay ( $191,829, FY2026 Q4 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation multiples over time Market data may be delayed

At fiscal year end 201820192020202120222023202420252026
Share price$97.39$30.06$3.78$1.76$1.69$0.35$1.16$1.18$2.28
Market value$3.1bn$1.1bn$123m$57m$67m$16m$55m$336m$1.6bn
+ Net debt (− = net cash)−$133m−$37m$13m−$15m−$18m−$8m−$85m−$176m−$170572
Enterprise value$3.0bn$1.0bn$136m$42m$49m$8m−$30m$160m$1.6bn
Multiples
Price / sales 28.8x12.8x17.8x32.7x11.2x1.2x22.7x22.8x119.1x
Price / earnings 47.3x191.7x———————
Price / free cash flow 35.5x——————n/m—
EV / EBITDA 38.9x————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for Akso Health Group: too few analysts cover it.

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2019 $0.00 −$0.45 0.0%
Mar 2019 −$0.30 $0.15 +150.0%
Dec 2018 −$0.78 −$0.60 +23.1%

Adjusted EPS as companies report it, against the average analyst estimate.

Positioning

Short interest
0.0%
of tradable shares
Days to cover
0.25
at average volume
Short interest, 1 month
+244%
to October 15, 2026
Held by institutions
0%
of shares
Held by insiders
0.0%
of shares
Employees
12
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
AHG−34%−77%+97%+84%+21%−20%
Industry peers (median)−1%−25%+6%−6%−9%+15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
AHG42%33%58%50%58%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
AHG−91%−84%−70%−75%−46%−72%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 3, 2017: 100% from November 16, 2017 to July 27, 2023. Getting back needed a 47897% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.69 – $2.50
From 52-week high
−47.5%
vs 50-day average
+27.8%
vs 200-day average
−13.2%
Volatility (1 year)
96%
Beta vs S&P 500
-0.08

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Akso Health Group in five measures

Fundamentals grade E
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Akso Health Group
$0 $50M $100M $150M FY17 Q4 FY19 Q4 FY21 Q4 FY23 Q4 FY26 Q4 Revenue (TTM), FY17 Q4: $22.9M Revenue (TTM), FY18 Q4: $107.3M Revenue (TTM), FY19 Q4: $82.6M Revenue (TTM), FY20 Q4: $6.9M Revenue (TTM), FY21 Q4: $1.8M Revenue (TTM), FY22 Q4: $6M Revenue (TTM), FY23 Q4: $13.2M Revenue (TTM), FY24 Q4: $2.4M Revenue (TTM), FY25 Q4: $14.8M Revenue (TTM), FY26 Q4: $13.8M $13.8M

Source: SEC EDGAR filings. Retrieved Invalid Date.

View chart data
Period Revenue (TTM)
FY17 Q4 $22.9M
FY18 Q4 $107.3M
FY19 Q4 $82.6M
FY20 Q4 $6.9M
FY21 Q4 $1.8M
FY22 Q4 $6M
FY23 Q4 $13.2M
FY24 Q4 $2.4M
FY25 Q4 $14.8M
FY26 Q4 $13.8M
Revenue growth, TTM YoY Akso Health Group
-200% 0% 200% 400% 600% FY18 Q4 FY20 Q4 FY22 Q4 FY24 Q4 FY26 Q4 Revenue growth, TTM YoY, FY18 Q4: 368.0% Revenue growth, TTM YoY, FY19 Q4: -23.0% Revenue growth, TTM YoY, FY20 Q4: -91.6% Revenue growth, TTM YoY, FY21 Q4: -74.6% Revenue growth, TTM YoY, FY22 Q4: 241.9% Revenue growth, TTM YoY, FY23 Q4: 119.7% Revenue growth, TTM YoY, FY24 Q4: -81.7% Revenue growth, TTM YoY, FY25 Q4: 512.1% Revenue growth, TTM YoY, FY26 Q4: -6.4% -6.4%

Source: SEC EDGAR filings. Retrieved Invalid Date.

View chart data
Period Revenue growth, TTM YoY
FY18 Q4 368.0%
FY19 Q4 -23.0%
FY20 Q4 -91.6%
FY21 Q4 -74.6%
FY22 Q4 241.9%
FY23 Q4 119.7%
FY24 Q4 -81.7%
FY25 Q4 512.1%
FY26 Q4 -6.4%
Operating margin (TTM) Akso Health Group
-1500% -1000% -500% 0% 500% FY17 Q4 FY19 Q4 FY21 Q4 FY23 Q4 FY26 Q4 Operating margin (TTM), FY17 Q4: 43.3% Operating margin (TTM), FY18 Q4: 70.7% Operating margin (TTM), FY19 Q4: -8.7% Operating margin (TTM), FY20 Q4: -695.7% Operating margin (TTM), FY21 Q4: -241.7% Operating margin (TTM), FY22 Q4: -54.3% Operating margin (TTM), FY23 Q4: -108.2% Operating margin (TTM), FY24 Q4: -357.8% Operating margin (TTM), FY25 Q4: -1125.4% Operating margin (TTM), FY26 Q4: -149.7% -149.7%

Source: SEC EDGAR filings. Retrieved Invalid Date.

View chart data
Period Operating margin (TTM)
FY17 Q4 43.3%
FY18 Q4 70.7%
FY19 Q4 -8.7%
FY20 Q4 -695.7%
FY21 Q4 -241.7%
FY22 Q4 -54.3%
FY23 Q4 -108.2%
FY24 Q4 -357.8%
FY25 Q4 -1125.4%
FY26 Q4 -149.7%
FCF margin (TTM) Akso Health Group
-1000% -500% 0% 500% FY17 Q4 FY19 Q4 FY22 Q4 FY26 Q4 FCF margin (TTM), FY17 Q4: 34.5% FCF margin (TTM), FY18 Q4: 81.4% FCF margin (TTM), FY19 Q4: -2.1% FCF margin (TTM), FY20 Q4: -845.7% FCF margin (TTM), FY22 Q4: -143.9% FCF margin (TTM), FY25 Q4: 6.9% FCF margin (TTM), FY26 Q4: -92.5% -92.5%

Source: SEC EDGAR filings. Retrieved Invalid Date.

View chart data
Period FCF margin (TTM)
FY17 Q4 34.5%
FY18 Q4 81.4%
FY19 Q4 -2.1%
FY20 Q4 -845.7%
FY22 Q4 -143.9%
FY25 Q4 6.9%
FY26 Q4 -92.5%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 20-F. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2017 Mar 2017 2018 Mar 2018 2019 Mar 2019 2020 Mar 2020 2021 Mar 2021 2022 Mar 2022 2023 Mar 2023 2024 Mar 2024 2025 Mar 2025 2026 Mar 2026
Income
Revenue 23 107 83 7 2 6 13 2 15 14
Gross profit 23 107 75 7 2 1 1 0 −0 −0
EBITDA 10 76 −7 −48 −4 −3 — — −164 −18
Operating income 10 76 −7 −48 −4 −3 −14 −9 −166 −21
Net income 9 65 6 −71 −35 −17 −1 −9 −135 −19
Diluted EPS $0.30 $2.06 $0.15 −$2.19 −$1.06 −$0.42 −$0.03 — — —
Growth (year on year)
Revenue — +368.0% −23.0% −91.6% −74.6% +241.9% +119.7% −81.7% +512.1% −6.4%
EBITDA — +660.1% −109.4% — — — — — — —
Operating income — +665.4% −109.5% — — — — — — —
Net income — +664.0% −91.6% <−999% — — — — — —
Diluted EPS — +585.0% −92.7% <−999% — — — — — —
Margins
Gross margin 100.0% 100.0% 91.0% 100.0% 100.0% 10.1% 9.6% 5.1% −1.9% −0.1%
EBITDA margin 43.7% 70.9% −8.7% −694.0% −240.8% −54.0% — — <−999% −132.5%
Operating margin 43.3% 70.7% −8.7% −695.7% −241.7% −54.3% −108.2% −357.8% <−999% −149.7%
Net margin 37.4% 61.1% 6.7% <−999% <−999% −280.9% −10.3% −391.8% −913.4% −135.0%
Free-cash-flow margin 34.5% 81.4% −2.1% −845.7% — −143.9% — — 6.9% −92.5%
Cash flow
Cash from operations 8 88 −2 −58 10 −9 −3 1 1 −13
Capital spending 0 0 0 0 — 0 — — 0 0
Free cash flow 8 87 −2 −58 — −9 — — 1 −13
Stock-based pay 0 2 7 0 0 0 — — — —
Free cash flow after stock pay 8 85 −8 −59 — −9 — — — —
Balance sheet
Cash 19 133 57 7 15 18 8 85 176 0
Total debt 0 0 20 20 — 0 0 0 0 0
Net debt (negative = net cash) −19 −133 −37 13 −15 −18 −8 −85 −176 −0
Diluted shares 28m 32m 35m 33m 33m 40m 46m 47m 285m 723m
Returned to shareholders
Dividends — — 20 — — — — — — —
Buybacks — — 1 3 — — — — — —
Total returned — — 21 3 — — — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · March 31, 2026
What it owns · $190m
Short-term assets $190mLonger-term assets $0m
What it owes, and who funded it · $190m
Short-term liabilities $9mLonger-term liabilities $0mShareholders' equity $181m
  • Short-term assets cover short-term liabilities $190m of assets due within a year against $9m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $190m short-term assets against $2,565 of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Akso Health Group's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+153.5%
year over year
Sales & admin spending
28.8%
of revenue
Days sales outstanding
34 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care services
Last 12 months unless stated AHG AMS CCEL HAO RDGT NRC Median
Revenue, last 12 months $14m $30m $31m $55m $132m $140m $1.2bn
Revenue growth, last 12 months −6.4% 4.0% −2.0% 67.1% 10.2% −0.2% 7.3%
Revenue growth, 3-year average — 14.3% −0.1% — — −1.9% 11.3%
Revenue growth, latest quarter — 19.2% −0.0% — — 4.0% 8.5%
Gross margin −0.1% 17.1% 78.5% 1.1% 3.6% — 27.9%
Operating margin −149.7% −11.8% 0.6% −17.6% −1.4% 10.5% 2.3%
Operating margin, 3-year average −44.4% −8.5% −8.4% — — 19.1% 2.3%
Net margin −135.0% −5.8% −6.2% −17.4% −0.9% 4.0% 1.2%
Cash from operations / revenue −92.5% 17.6% 15.8% −4.7% −1.1% 21.1% 6.1%
Free-cash-flow margin −92.5% 11.6% 14.9% −5.2% −1.1% 15.5% 5.1%
Free-cash-flow margin, 3-year average — −14.8% 14.7% — — 12.5% 3.6%
Stock pay / revenue 6.5% 1.3% 1.1% 0.2% 8.6% 8.4% 1.1%
Change in share count 153.5% 0.4% −1.4% >999% 96.6% −5.2% 0.3%

Median of all 41 companies we cover in health care services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

41 health care services companies
Measure Company Peer median Rank
Revenue growth Growth -6.4% 7.3% 34 of 41
Change in growth rate Growth -518.5pp +1.1pp 41 of 41
Gross margin Profitability -0.1% 29.0% 27 of 27
Operating margin Profitability -149.7% 2.6% 38 of 40
Net margin Profitability -135.0% 1.2% 40 of 41
Free-cash-flow margin Cash generation -92.5% 5.1% 39 of 40
Change in share count Balance sheet 153.5% 0.4% 38 of 39
Days sales outstanding Balance sheet 34 days 39 days 9 of 31

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$419,651
Institutions reporting
11
Shares held vs prior quarter
▲ 24.1%
Positions opened / closed
5 / 0

Top buyers and sellers, Q2 2026: 9 institutions bought and 1 sold ; the biggest buyer was Citadel Advisors LLC (+46K shares) and the biggest seller Renaissance Technologies LLC (−27K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Renaissance Technologies LLC $105,705 71K 25.2% ▼ 27.9%
Northern Trust Corp $76,590 51K 18.3% ▲ 9.7%
Citadel Advisors LLC $68,579 46K 16.3% New
Smartharvest Portfolios, LLC $66,685 45K 15.9% ▲ 26.3%
Jane Street Group, LLC $61,626 41K 14.7% ▲ 32.4%
Geode Capital Management, LLC $22,309 15K 5.3% 0.0%
Blackrock, Inc. $14,995 10K 3.6% ▲ 27100.0%
UBS Group AG $1,434 1K 0.3% New
Morgan Stanley $1,101 1K 0.3% New
Huntington National Bank $624 0K 0.1% New
Caitong International Asset Management Co., Ltd $3 0K 0.0% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Akso Health Group's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

Data status

When each part of this page on Akso Health Group was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Akso Health Group in brief

What does Akso Health Group do?
Akso Health Group is a US-listed company in the health care services industry. Its financial year ends in March.
What is Akso Health Group's stock ticker?
Akso Health Group trades under the ticker AHG on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Akso Health Group's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Akso Health Group reported revenue of $13.8M, 6.4% lower than a year earlier, according to its SEC filings.
What is Akso Health Group's free cash flow?
Akso Health Group's free-cash-flow margin is -92.5% of revenue over the trailing twelve months, ranking 39 of the 40 health care services companies we cover.
Who are Akso Health Group's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Renaissance Technologies LLC, Northern Trust Corp and Citadel Advisors LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Akso Health Group's market cap?
On March 31, 2026, Akso Health Group's market capitalisation was about $1.6B and net debt of -$170,572. Market figures come from third-party market data and may be delayed.
Who are Akso Health Group's competitors?
In our Health Care Services peer group, the companies closest to Akso Health Group are American Shared Hospital Services, Cryo Cell International Inc, Haoxi Health Technology Ltd, Ridgetech Inc. and NRC Health. The side-by-side comparison below sets their revenue, margins and growth against Akso Health Group's.